Objectives: Heterogeneity in sepsis-related pathobiology presents a significant challenge. Resolving this heterogeneity presents an opportunity to understand pathobiology and improve patient care. Olfactomedin-4 is a neutrophil subset marker and may contribute to sepsis heterogeneity. Our objective was to evaluate the expression of olfactomedin-4 and characterize neutrophil heterogeneity in children with septic shock. Design: Single-center, prospective cohort, as well as secondary analysis of existing transcriptomic and proteomic databases. Setting: Tertiary care PICU. Patients: Patients from 5 days to 18 years old with septic shock were enrolled. Data collected included the expression of olfactomedin-4 messenger RNA, serum protein concentrations, and percentage of neutrophils that express olfactomedin-4. Interventions: None. Measurements and Main Results: Secondary analysis of existing transcriptomic data demonstrated that olfactomedin-4 is the most highly expressed gene in nonsurvivors of pediatric septic shock, compared with survivors. Secondary analysis of an existing proteomic database corroborated these observations. In a prospectively enrolled cohort, we quantified the percentage of olfactomedin-4+ neutrophils in patients with septic shock. Patients with a complicated course, defined as greater than or equal to two organ failures at day 7 of septic shock or 28-day mortality, had a higher percentage of olfactomedin-4+ neutrophils, compared with those without a complicated course. By logistic regression, the percentage of olfactomedin-4+ neutrophils was independently associated with increased risk of a complicated course (odds ratio, 1.09; 95% CI, 1.01-1.17; p = 0.024). Conclusions: Olfactomedin-4 identifies a subpopulation of neutrophils in patients with septic shock, and those with a high percentage of olfactomedin-4+ neutrophils are at higher risk for greater organ failure burden and death. Olfactomedin-4 might serve as a marker of a pathogenic neutrophil subset in patients with septic shock. (Crit Care Med 2017; 45:e426-e432) 
S epsis and septic shock are major causes of morbidity and mortality in all ICUs throughout the world. Mortality rates from septic shock have improved over the past few decades, but remain unacceptably high (1, 2) . Research has led to a better understanding of the pathologic mechanisms of sepsis; however, clinical care has remained much the same for many years (3, 4) . Virtually, all recent clinical trials have failed to show improved outcomes, much of this because of the heterogeneity in the patients who are enrolled. This heterogeneity comes from many sources including initiating infection, host immune-competence, morbidities, and notable differences in immunopathobiology. There is a significant need for breakthroughs in understanding to identify novel therapeutic pathways that will also lead to increased ability to categorize patients with septic shock.
Neutrophils are the primary leukocyte in the blood and are the first line response to onset of infection. Neutrophils contain both pattern recognition immune receptors and Fc receptors that allow participation in both innate and adaptive immune responses. Characteristics of neutrophils in terms of count, maturity, migration, and granularity have been characterized in patients with septic shock, but only absolute neutrophils count and the presence Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ ccmjournal).
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Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock
Matthew N. Alder, MD, PhD 1, 2 ; Amy M. Opoka, BS 1 of bands are used clinically (5) . Although lymphocytes have been subdivided into many subpopulations with unique immune roles, neutrophil heterogeneity that can associate different functions within neutrophil subsets has been postulated, but no definitive subpopulations or states have been characterized (6, 7) .
Olfactomedin-4 (OLFM4) was originally identified as a granular protein induced with granulocyte colony-stimulating factor and expressed in mature granulocytes in mice (8, 9) . Subsequent work focused on the finding that OLFM4 was also expressed in human intestinal tumors, particularly gastric cancer where it was shown to have antiapoptotic properties (10, 11) . A mouse deficient of OLFM4 appeared to be phenotypically normal, but when challenged with intraperitoneal injection of Staphylococcus aureus, was protected from death when compared with wild type littermates (12, 13) . OLFM4 messenger RNA (mRNA) has also been shown to be up-regulated in the human disease such as respiratory syncytial virus bronchiolitis in pediatric patients and acute respiratory distress syndrome in adults (14, 15) . More recently, two groups reported OLFM4 expression in a subset of human neutrophils, but were unable to identify a phenotypic difference between the OLFM4 positive and negative neutrophil populations (16, 17) .
We sought to identify novel pathways in immune cells during septic shock that may help explain the dynamic fluctuations and heterogeneity in patients. Review of a transcriptomic database reflecting whole blood-derived RNA revealed OLFM4 as significantly up-regulated in these patients. Given the finding that OLFM4 is expressed in a subset of neutrophils, upregulated in several illnesses in adult and pediatric patients, and the OLFM4 null mouse had improved mortality when challenged with a lethal dose of bacteria, we set out to characterize the expression of OLFM4 in pediatric patients with septic shock.
MATERIALS AND METHODS

Transcriptomic and Proteomic Data
OLFM4 mRNA expression data were extracted from an existing, microarray-based transcriptomic database. Details of the study protocol were previously published (18, 19) and the data are deposited in the Gene Expression Omnibus (accession number: GSE66099). Briefly, the data reflect children with septic shock and normal controls. The RNA used for microarray analyses was derived from whole blood obtained within the first 24 hours of meeting criteria for septic shock. The original consent form for this protocol allows for secondary analysis of clinical and biologic data.
OLFM4 serum protein concentration data were extracted from an existing proteomic database generated during the derivation and validation of a panel of biomarkers to estimate the probability of sepis-associated acute kidney injury (20) . The serum samples were obtained within the first 24 hours of meeting criteria for septic shock. The protocol for patient enrollment was previously published (20) and the original consent form allows for secondary analyses of clinical and biologic data. For new patients (described below), similar protocol was used except that OLFM4 was measured in the plasma rather than the serum.
Prospective Enrollment of Study Subjects and Data Collection
The protocol for prospective collection and use of biologic samples and clinical data was approved by the Institutional Review Board of Cincinnati Children's Hospital Medical Center. Children 18 years old or younger admitted to the PICU and meeting pediatric-specific consensus criteria for systemic inflammatory response syndrome (SIRS), sepsis, or septic shock were eligible for enrollment (21) . The only exclusion criteria were the presence of neutropenia, which precludes our flow cytometry protocol, and the inability to obtain informed consent, which was obtained from parents or legal guardians before any data or sample collection.
Whole blood samples for flow cytometry were obtained within 24 hours of first meeting the criteria for SIRS, sepsis, or septic shock in the PICU, which was typically at presentation to the PICU. These are referred to as "day 1" samples. Fortyeight hours later, a second whole blood sample was obtained for flow cytometry, termed "day 3" samples. Clinical and laboratory data were collected daily while in the PICU. Organ failure data were tracked up to day 7 using previously published criteria (21) . Mortality was tracked for 28 days after enrollment. Illness severity was estimated using the Pediatric Risk of Mortality (PRISM) score, which is based on laboratory values and clinical variables reflecting physiology (22) . Control whole blood samples were obtained from children presenting to the same day surgery department for elective hernia repairs. The control subjects were otherwise healthy, and had no history of a febrile illness or exposure to anti-inflammatory medications in the preceding 2 weeks.
Flow Cytometry
Flow cytometric staining of cells for OLFM4 expression was done as previously described by Welin et al (17) . Our protocol is described in the online supplemental data (Supplemental Digital Content 1, http://links.lww.com/CCM/C179).
Statistical Analysis
Statistical procedures used SigmaStat Software (Systat Software, San Jose, CA). Initially, data are described using medians, interquartile ranges, frequencies, and percentages. Comparisons between groups used the Mann-Whitney U test, chisquare, or Fisher exact tests as appropriate. For analysis of the flow cytometry data, we combined the subjects with SIRS or sepsis into a single group referred to as "PICU controls." For logistic regression, we used complicated course as the primary outcome variable. This is defined as persistence of two or more organ failures at day 7 of septic shock or 28-day mortality (19, (23) (24) (25) (26) (27) (28) . We have used this outcome variable in previous studies because persistent, multiple organ failure is a major antecedent of death from septic shock. Using complicated course in the logistic regression modeling allows the exploration of association between percentage of OLFM+ neutrophils and a nuance of sepsis severity beyond the dichotomy of "alive" versus "dead." In addition to the percentage of OLFM4+ neutrophils, the logistic regression modeling considered age and illness severity as independent variables. Statistical methods for gene array data are described in the supplementary methods (Supplemental Digital Content 1, http://links.lww.com/ CCM/C179).
RESULTS
OLFM4 mRNA Expression
The clinical and demographic data for the study subjects in the transcriptomic database were previously published (18) . Supplementa1 Table 1 (Supplemental Digital Content 2, http://links.lww.com/CCM/C180) shows the top five most up-regulated genes in the subjects with septic shock who did not survive (n = 29), compared with those who survived (n = 151). OLFM4 was the most highly expressed gene in the nonsurvivors based on a fold expression criterion and a Benjamini-Hochberg false discovery rate of 5%. OLFM4 mRNA expression was greater in the nonsurvivors, compared with the survivors (Fig. 1A) . Similarly, Figure 1B shows that OLFM4 mRNA expression was greater in the patients with septic shock and a complicated course (n = 53), compared with those without a complicated course (n = 127).
OLFM4 Protein in Serum
Given the increase in OLFM4 transcript expression, we next evaluated the plasma protein concentration. The clinical and demographic data for the study subjects in the proteomic database were previously published (20) . We measured baseline OLFM4 serum concentration in 22 healthy pediatric controls (mean, 0.93 ng/mL; range, 0.17-3.0 ng/mL) and compared it with 450 patients with septic shock (mean, 86.3 ng/mL; range, 0.04-867.4 ng/mL). Figure 2A compares OLFM4 serum concentrations between patients with septic shock who survived the 28-day study period (n = 388) and those who did not (n = 62). There was trend toward increased OLFM4 serum protein concentrations in the nonsurvivors, but this did not reach statistical significance (p = 0.099). However, when comparing OLFM4 serum concentrations between patients with septic shock without a complicated course (n = 316) and those with a complicated course (n = 134), the median OLFM4 serum concentrations was significantly higher in the patients with a complicated course (Fig. 2B) . Critical Care Medicine
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Flow Cytometric Measurement of OLFM4+ Neutrophils We next sought to evaluate whether patients with septic shock had different percent of neutrophils that express OLFM4. Table  1 shows the clinical and demographic data for the prospectively enrolled study subjects who were evaluated by flow cytometry for OLFM4+ neutrophils. The subjects in the PICU control group were older than the subjects in the healthy control group. PRISM scores were greater in the septic shock group, compared with the PICU control group. No other differences were noted. Figure 3A shows a representative flow cytometry analysis from a single patient with septic shock. The left figure shows the initial gating of the WBC population. The right figure shows two distinct populations of neutrophils based on negative or positive staining for OLFM4. We did not observe significant fluctuation in the mean fluorescence intensity (MFI), a surrogate measure of the amount of protein (data not shown).
We also evaluated the percentage of OLFM4+ neutrophils on day 1, between healthy controls, PICU controls, and subjects with septic shock (Fig. 3B) . The median percentage of OLFM4+ neutrophils was not different between the three groups. Figure 3C compares the percentage of OLFM4+ neutrophils on day 1, between subjects with septic shock without a complicated course and those with a complicated course. The percentage of OLFM4+ neutrophils was higher in the subjects with a complicated course. Supplemental Figure 1, A and B (Supplemental Digital Content 3, http://links.lww.com/CCM/ C181; legend, Supplemental Digital Content 5, http://links. lww.com/CCM/C183) shows similar analyses, but represent day 3 samples. The day 3 observations were similar to that seen on day 1. We also evaluated whether OLFM4 may be expressed by immature neutrophils, or bands, and found no correlation between band count and percent of OLFM4+ neutrophils (n = 39; R value, 0.100; p = 0.58).
Logistic regression modeling to test for an association between the percentage of OLFM4+ neutrophils and complicated course among subjects with septic shock is shown in Table 2 . The percentage of OLFM4+ neutrophils on day 1 of septic shock was independently associated with increased odds of a complicated course (OR, 1.09; 95% CI, 1.01-1.17; p = 0.024), even when accounting for the age and degree of illness severity (PRISM score). A similar trend was observed when analyzing the percentage of OLFM4+ neutrophils on day 3 of septic shock, but this was marginally significant.
To test whether neutrophils are the source for serum OLFM4, we examined the correlation between the percentages of OLFM4+ neutrophils and serum OLFM4 concentrations (Supplemental Fig. 2A 
DISCUSSION
In these cohorts of children with septic shock, OLFM4 transcript was highly up-regulated in those with a complicated course and was the most up-regulated gene in those who died compared with those who survived. The mRNA up-regulation was concomitant with a nearly 100-fold increase in serum protein concentration in patients with septic shock compared with healthy controls. Finally, in pediatric patients admitted to the ICU, there was no difference in the mean percentage of OLFM4+ neutrophils between healthy controls, PICU controls (SIRS and sepsis), and those with septic shock; however, a high percent of OLFM4+ neutrophils increased the likelihood of having a complicated course from septic shock (Figs. 3, B and C). This association was independent of illness severity and age. Collectively, these data indicate that OLFM4+ neutrophils are not associated with the risk of developing septic shock per se, but among those with septic shock they are associated with increased odds of having greater organ failure and death. Neutrophils have long been recognized as the primary innate immune cell in the blood. Although lymphocytes have been differentiated into many subpopulations with different effector function, neutrophils have been primarily classified by age (young vs old), activation status, or by location (marrow, blood, or extravasated into tissue) (7, 29, 30) . Surface markers have greatly facilitated the differentiation of lymphocyte subpopulations, but there are few surface makers that differentiate neutrophils. CXCR4 and CD16 expression have been used to differentiate aged neutrophils (29) ; CD177 has been shown to have bimodal expression on neutrophils that differs between individuals with increased expression during certain inflammatory states (31, 32) . To date, CD177 and OLFM4 remain the best markers for isolating bimodal neutrophil subpopulations, but there is little evidence for functional differences in these subpopulations. Two groups have started the characterization of the OLFM4+ neutrophils. Clemmensen et al (16) first showed the OLFM4 mRNA was expressed in all neutrophils during development, but only in a subpopulation of mature granulocytes. Welin et al (17) found OLFM4 positive and negative neutrophils had similar activation, phagocytosis, and apoptosis. They also found that OLFM4 was located in neutrophils neutrophil extracellular traps (NETs) and speculated it may play a role in NETosis. Here we present OLFM4 is highly up-regulated in patients with septic shock and the degree of up-regulation is associated with clinical outcomes, suggesting a potential role for this subpopulation of neutrophils.
When comparing patients who survived septic shock with those who did not, OLFM4 transcript had the highest fold Critical Care Medicine www.ccmjournal.org e431 increase of any gene from all leukocytes (neutrophils, monocytes, and lymphocytes), yet OLFM4 is only expressed in a subset of neutrophils bases on flow cytometric analysis. We envision a few likely explanations for this observation. First, it could be that 25-50% of neutrophils account for the significant increase in mRNA transcriptional fold expression and other neutrophils never express OLFM4. Another explanation would be that all neutrophils express OLFM4 but that it is translated and rapidly secreted in some neutrophils or that the mRNA transcript never undergoes translation. Both interpretations suggest that there are separate subpopulations or at least states of neutrophils. In addition, there was no correlation between immature neutrophil bands and percentage of OLFM4+ neutrophils suggesting OLFM4 is not simply a marker of recently emigrated neutrophils. Although there were changes in MFI between patients and days 1 and 3, there was no consistent pattern to suggest an increase in secretion (decrease MFI; data not shown).
Increased transcriptional activity of OLFM4 was concurrent with a dramatic increase in plasma protein concentration. Under healthy conditions, OLFM4 is known to be expressed by the prostate, intestine, and neutrophils. Patients with inflamed ulcerative colitis have been shown to produce OLFM4 in intestinal crypt cells and secrete it into the intestinal lumen (33) . Other groups have attempted to identify a source of the serum OLFM4, but to date no definitive source has been identified (34) . The expression of OLFM4 protein in the specific granules of neutrophils suggests that some plasma OLFM4 may be coming from neutrophil exocytosis. In patients with septic shock, serum OLFM4 increased with increasing percentages of OLFM4+ neutrophils, but these was substantial scatter about the regression line, suggesting neutrophils contribute but are not the only source of OLFM4 serum concentrations. Further evidence that there is another source comes from patients with a low absolute neutrophil count that still have high serum OLFM4. An additional complicating factor is the recent finding that OLFM4 can serve as an autoantigen and some patients carry antibodies specific to OLFM4, which may also result in clearance of some of the plasma OLFM4 (35) . Thus, the additional sources and function of a near 100-fold increase in plasma OLFM4 in patients with septic shock remains unknown at this time.
The question remains whether the high concentration of OLFM4 in the plasma is simply a marker of cellular damage, or whether there is a functional role for the OLFM4 protein.
The strongest evidence for OLFM4 actually playing a role in pathology is the finding that OLFM4-deficient mice are protected from death when injected with S. aureus and Escherichia coli (13) . The authors who generated this mouse also found that OLFM4 inhibited cathepsin C, a serine protease important for activation of several proteases with putative-antimicrobial activity, and postulated that the loss of OLFM4 increased cathepsin C activity, thereby providing protection. However, crossing OLFM4 onto a cathepsin C-deficient mouse still provided protection, suggesting alternative mechanisms. Also, it is difficult to make physiologic sense that the most up-regulated genes in neutrophils from patients with septic shock are those to inhibit antimicrobial activity, again suggesting there may be alternative functions for OLFM4.
CONCLUSIONS
The balance between an over exuberant immune response and one that controls the initiating infection remains a fundamental problem in the management of patients with septic shock. Massive stimulation of immune cells leads to a cytokine storm that often leads to the clinical presentation of septic shock with endothelial injury, coagulopathy, and vasodilation. Following initial presentation, patients are left in fluctuating state of chronic activation of some cells, while other immune cells are exhausted from over stimulation and rendered useless. Our goal is to identify specific immunologic pathways or cellular subpopulations that might be targeted to tone down an immune response to temper host damage but still allow for a pathogen clearing immune responses. Toward this direction, we identified a difference in neutrophil populations that correlate with disease severity, and may one day be eligible for targeting of specific neutrophil subpopulations, pathologic and nonpathologic. 
